Tuesday, January 30, 2024

AcuraStem Snags $7M In Grant Funding for ALS, Dementia Treatment

Pasadena-based AcuraStem, a biotechnology company developing treatments for amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and other neurodegenerative diseases, says it has received $7M in a grant funding. The company said the funding came from the National Institutes of Health (NIH) and the Department of Defense (DOD). AcuraStem says it already has a $580M licensing agreement with Takeda to develop and commercialize one of its therapeutics.